JPWO2020198587A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020198587A5
JPWO2020198587A5 JP2021557634A JP2021557634A JPWO2020198587A5 JP WO2020198587 A5 JPWO2020198587 A5 JP WO2020198587A5 JP 2021557634 A JP2021557634 A JP 2021557634A JP 2021557634 A JP2021557634 A JP 2021557634A JP WO2020198587 A5 JPWO2020198587 A5 JP WO2020198587A5
Authority
JP
Japan
Prior art keywords
subject
igf
odn
administered
cell function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527473A (ja
JP2022527473A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025217 external-priority patent/WO2020198587A1/en
Publication of JP2022527473A publication Critical patent/JP2022527473A/ja
Publication of JPWO2020198587A5 publication Critical patent/JPWO2020198587A5/ja
Publication of JP2022527473A5 publication Critical patent/JP2022527473A5/ja
Priority to JP2025031086A priority Critical patent/JP2025098027A/ja
Pending legal-status Critical Current

Links

JP2021557634A 2019-03-28 2020-03-27 アンチセンスを用いてがんを治療するための方法 Pending JP2022527473A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031086A JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825516P 2019-03-28 2019-03-28
US62/825,516 2019-03-28
PCT/US2020/025217 WO2020198587A1 (en) 2019-03-28 2020-03-27 Methods for treating cancers using antisense

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031086A Division JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Publications (3)

Publication Number Publication Date
JP2022527473A JP2022527473A (ja) 2022-06-02
JPWO2020198587A5 true JPWO2020198587A5 (https=) 2023-04-04
JP2022527473A5 JP2022527473A5 (https=) 2023-04-04

Family

ID=72609134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557634A Pending JP2022527473A (ja) 2019-03-28 2020-03-27 アンチセンスを用いてがんを治療するための方法
JP2025031086A Pending JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031086A Pending JP2025098027A (ja) 2019-03-28 2025-02-28 アンチセンスを用いてがんを治療するための方法

Country Status (7)

Country Link
US (1) US20220195440A1 (https=)
EP (1) EP3946287A4 (https=)
JP (2) JP2022527473A (https=)
AU (1) AU2020244865A1 (https=)
CA (1) CA3134969A1 (https=)
MX (1) MX2021011760A (https=)
WO (1) WO2020198587A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
EA201992485A1 (ru) 2017-04-19 2020-02-17 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования stat3
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541036B1 (en) * 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
WO2002027019A1 (en) * 2000-09-29 2002-04-04 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
NZ554831A (en) * 2004-11-09 2009-10-30 Schering Corp Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
EP1900825A1 (en) * 2006-09-13 2008-03-19 Rheinische Friedrich-Wilhelms-Universität Bonn Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2016164916A1 (en) * 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
US10357509B2 (en) * 2017-03-09 2019-07-23 Thomas Jefferson University Methods and compositions for treating cancers using antisense

Similar Documents

Publication Publication Date Title
CN106191062B (zh) 一种tcr-/pd-1-双阴性t细胞及其构建方法
JP2020518256A5 (https=)
Mason et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy
JP2020532955A5 (https=)
JP2024096899A5 (https=)
JP2018500006A5 (https=)
JP2017071638A (ja) インサイチュー抗原生成癌ワクチン
JP2025085731A5 (https=)
CA3011933A1 (en) Oncolytic viral vectors and uses thereof
EP4069284A1 (en) Tumor cell vaccines
Wang et al. Autophagy and gastrointestinal diseases
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
JP2005523277A5 (https=)
KR102400622B1 (ko) 진저론을 유효성분으로 포함하는 난청 예방 또는 치료용 조성물
Xiao et al. Clostridium butyricum partially regulates the development of colitis-associated cancer through miR-200c
AR015926A1 (es) Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades
JP2011519869A5 (https=)
Álvarez‐Rodríguez et al. Recent advances in uveal melanoma treatment
CN116196437B (zh) 红细胞负载溶瘤病毒静脉递送制剂的制备及其抗肿瘤应用
Yu et al. Different responses of tumor and normal cells to low-dose radiation
JPWO2020198587A5 (https=)
Chen et al. Nanomedicine strategies for ameliorating cancer by targeting immunosenescence: From challenge to opportunity
JPWO2021136263A5 (https=)
WO2004013313A3 (en) Antisense nucleic acids
Wang et al. Near infrared light activation of an injectable whole-cell cancer vaccine for cancer immunoprophylaxis and immunotherapy